Cambridge Heart Schedules Third Quarter Earnings Conference Call.

BEDFORD, Mass. -- Cambridge Heart, Inc. (OTCBB-CAMH) today announced that Mr. David Chazanovitz, President and CEO has scheduled his third quarter earnings conference call for Thursday, November 4, 2004 at 4:30 p.m. eastern to discuss the Company's third quarter financial results, as well as recent Company developments. Interested parties may participate by dialing [phone] and [phone] from outside the U.S.

Persons unable to participate may listen to a recorded replay at any time during the 48 hours immediately following the conference call by dialing [phone] or [phone] from outside the U.S. The code for the replay is 1163. The replay will be available beginning approximately two hours after the call ends. The conference call will also be available by webcast on the Company's web site at www.cambridgeheart.com.

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

About Cambridge Heart, Inc.

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, the Microvolt T-Wave Alternans Testing System, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans using the Analytic Spectral Method. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.